Search

Displaying results 1411 - 1420 of 10000 in total
  1. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    [A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. … Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001.

    Products: IMATINIB DR. REDDY'S, IMATINIB AL 100 MG FTA
  2. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [L42330] LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union.

    Categories: Botulinum Toxins, Type ASynonyms: BoNT/A-DS
  3. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: Card-floe II Tab, INYECCIÓN DE TRAVASOL 10 % SIN ELECTROLITOSSynonyms: DL-Methionine, DL-Methioninum
  4. Drug

    Iophendylate

    go.drugbank.com/drugs/DB01187
    Approved

    It next appeared on the world scene for high volume (12-15cc), routine use, in diagnosing disc herniations. A number of clinicians have published on the dangers of oil myelography. … In 1942 Van Wagenen (a neurosurgical colleague of Warrens, at the University of Rochester) identified Iophendylate as causing chemical meningitis in 30 patients where "space-displacing masses within the

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses. … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  6. Drug

    Dihydro-alpha-ergocryptine

    go.drugbank.com/drugs/DB11274
    Approved

    Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]

  7. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition … It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients.

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  8. Drug

    Methscopolamine

    go.drugbank.com/drugs/DB11315
    Approved

    Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. … Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products.

    Mixtures: Allergy DN II, Allergy DN II
  9. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    It is marketed as Galvus.[L32803] Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy. … [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea

    Mixtures: GLIMETAL-DP, Vildagliptin/Metformin 1A Pharma 50 mg/850 mg – FilmtablettenCategories: Drugs Used in Diabetes, DPP-IV Inhibitors
  10. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide